Physician profile
Jerwin Wu
NPI 1346238854
$1,730.68
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,731.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akcea Therapeutics, INC. | $397.38 | 2019 | |
| Novartis Pharmaceuticals Corporation | $339.60 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $255.79 | 2019 | |
| Amgen INC. | $191.11 | 2019 | |
| Adamas Pharmaceuticals, INC. | $172.99 | 2019 | |
| Alexion Pharmaceuticals, INC. | $149.39 | 2019 | |
| Angiodynamics, INC. | $148.25 | 2019 | |
| Mdd US Operations, LLC | $27.50 | 2019 | |
| Acadia Pharmaceuticals INC | $24.67 | 2019 | |
| Abbvie INC. | $24.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerwin Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.